<DOC>
	<DOCNO>NCT01508416</DOCNO>
	<brief_summary>Patients Multiple Myeloma ( MM ) increase risk venous thromboembolic event , especially newly diagnose patient induction treatment thalidomide combination dexamethasone . This association mainly heighten 3 first month chemotherapy . Several coagulation abnormality describe . Laboratory test measure overall thrombophilic tendency might useful assess thrombosis risk . The aim study compare thrombin generation calibrate automated thrombogram 3 first cycle chemotherapy patient newly diagnose MM .</brief_summary>
	<brief_title>Study Thrombin Generation During 3 First Cycles Chemotherapy Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>Inscription medical assurance Patients give write consent Patients newly diagnose Multiple Myeloma require chemotherapy Patients renal failure need undergo hemodialysis Patients indication curative anticoagulant therapy Patient 3 month followup possible Patient life expectancy &lt; 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Newly diagnose</keyword>
	<keyword>Thrombin generation</keyword>
	<keyword>TFPI</keyword>
	<keyword>Tissue Factor pathway inhibitor</keyword>
	<keyword>Protein S</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>